Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesityEli Lilly and Company has announced positive topline results from the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide...
Journal Watch 17/04/2024Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
The status of bariatric surgery in EgyptWith approximately 100 million inhabitants, Egypt is the 14th-most populated country in the world, and the third-most populated in...
The evolution of the UK’s National Bariatric Surgery RegistryIn October 2023, Mr Omar Khan was appointed as the Chair of the British Obesity & Metabolic Surgery Society’s (BOMSS) National Bariatric...
Endoscopic sleeve gastroplasty more cost-effective than with semaglutideAn economic evaluation comparing endoscopic sleeve gastroplasty (ESG) with semaglutide for treating class II obesity has suggested ESG is...
Looking forward to IFSO 2024This year’s 27th IFSO World Congress returns to Australia for the first time since the 11th World Congress in Sydney in 2006. We caught...
Standardisation of OAGB is key to reducing surgical errors and ensuring consistent patient outcomes3 hours ago